HEALTH

Wyeth-Ayerst, Interneuron Change Redux Labeling: Wyeth-Ayerst, a unit of Madison, N.J.-based American Home Products Corp., and Interneuron Pharmaceuticals Inc. said they will change the label on their anti-obesity drug Redux to show it causes a higher rate of a dangerous lung disorder than previously expected. Redux is the first drug approved for obesity in 20 years and the only one sanctioned for chronic use to maintain weight loss. Analysts expect yearly sales of Redux to reach $200 million--provided that patients continue to refill their prescriptions. Redux, which it co-markets with Wyeth-Ayerst, is Lexington, Mass.-based Interneuron’s lead product.